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CHAPTER I 
 
 
INTRODUCTION 
 
Osteoporosis and osteopenia are major health threats to more than 50% of the female 
American population over age 50 [1].  An estimated 44 million Americans are affected by 
osteoporosis and osteopenia.  Osteoporosis is a disease characterized by low bone mass and 
structural deterioration of bone tissue, resulting in poor bone quality, reduced bone strength, and 
an increased risk for bone fracture, particularly in the hip, spine and wrist [1, 2].   
Fractures of the hip often require hospitalization and surgery and can impair an 
individual’s ability to walk, create a permanent disability, and may even result in death [1, 3].  
Vertebral fractures can cause severe back pain, deformity and loss of height [1].  In the USA, 
approximately 1.5 million fractures are attributable to osteoporosis every year [3] and $19 billion 
dollars were spent on osteoporosis-related fractures in 2005 [1].  It is predicted that the incidence 
of osteoporotic fractures will reach catastrophic proportions with a four-fold increase of 
osteoporosis worldwide over the next 50 years [3]. The costs associated with bone fractures will 
threaten the viability of health care systems in many countries [3] indicating an emergent need for 
preventative action.    
Postmenopausal osteoporosis accounts for 80% of osteoporosis cases that develop [4].  
The decline in sex steroids that occurs with the loss in ovarian function at menopause results in 
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changes in calcium homeostasis resulting in a negative calcium balance [5].  Estrogen deficiency 
also increases the production of inflammatory cytokines resulting in a further increase in bone 
resorption [4, 6, 7].  Considering the high prevalence of postmenopausal osteoporosis and the 
associated decline in sex hormone production, an option to prevent or reverse postmenopausal 
osteoporosis is needed.  For this study, the ovariectomized mouse is used as a model to emulate 
the hormonal effects in a postmenopausal state. 
Lifestyle modifications through diet may be a significant approach in preventing the 
development of osteoporosis [1].  Although much research has been conducted on the beneficial 
effects of dairy products and vitamin D in preventing bone loss, there are some important factors 
to consider with widespread dairy promotion as a dietary approach to bone health.  The first 
issue is that over two thirds of the world’s adult populations (approximately 30 to 50 million 
Americans; 75 % of African Americans and Native Americans and 90 % of Asian Americans) 
are lactose intolerant [8].  Also, with the recommended daily allowance (RDA) of calcium set at 
1200 mg per day for older adults, many individuals find it difficult to meet calcium requirements 
through dietary intake.  With milk being an excellent source of calcium, it can be challenging for 
individuals to drink four glasses of milk a day.  Another interesting point to consider is that the 
USA is one of world’s greatest consumers of dairy products, yet globally, has one of the highest 
rates of osteoporosis [3].  When considering these facts, the need for research into other nutrients 
that may promote bone growth and/or protect an individual from age- or menopause-induced 
bone loss becomes evident.   
Another factor promoting further research into dietary approaches for osteoporosis 
prevention is the fact that the commonly used osteoporotic medications, although effective, are 
associated with undesirable side effects.  For example, bisphosphonates have been associated 
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with bone, joint and/or muscle pain and most commonly reported, stomach upset and heartburn 
[9]
 .  Although uncommon with typical health care administration of the drug, a rapid injection of 
bisphosphonates can cause renal failure[9].  Oral administration of bisphosphonates, particularly 
with amines, can cause esophageal and gastrointestinal distress such as nausea, dyspepsia, 
vomiting, gastric pain, diarrhea, and ulceration[9].  Estrogen therapy, although not encouraged 
due to its serious side effects, has been associated with endometrial and breast cancer, vaginal 
bleeding, breast tenderness, gallbladder disease, strokes, heart attacks, venous blood clots and 
cognitive decline [1].  Selective estrogen receptor modulators (SERM), such as Raloxifene, are 
more commonly used and do not have the majority of side effects common to estrogen therapy 
but may induce hot flashes, blood clots in the legs or lungs, and strokes in those with coronary 
artery disease[10].  Teriparatide, a recombinant parathyroid treatment, has been associated with 
leg cramps, headache and myalgia[11].  In addition to these side effects, long term oral drug 
compliance can be challenging for many.  Research has shown that women taking oral 
bisphosphonates stop treatment or take less than what was prescribed, reducing the effectiveness 
of the medication.  Hence, there is a need for alternative prevention strategies with fewer side 
effects.  Dietary interventions that are effective, inexpensive, and can easily be incorporated into 
an individual’s daily diet deserves further research.   
Consumption of fruits and vegetables or the phytonutrients derived from them has been 
associated with reduced risk of osteoporosis in human observational studies or an increase in 
bone mineral density (BMD) in animals [12], [13] [14, 15] [16], [17],[18].  Fruits and vegetables contain a 
wide variety of vitamins and minerals as well as bioactive phytochemicals which may contribute 
to bone health.  Phytochemicals are non-nutritive food chemicals that the plant uses to protect 
itself from the external environment.  These same chemicals also may help to prevent disease in 
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humans by functioning as an antioxidant or hormone, stimulate enzymes, interfere with DNA 
replication or have an antibacterial affect [19].  Fruits and vegetables have antioxidant and anti-
inflammatory properties and reduce the renal acid load, actions which may also function as bone-
sparing agents [20-24], [25].  Aging and sex hormone related changes cause inflammation and pro-
oxidant conditions in the bone environment which are involved in the development of 
osteoporosis [26].  Women with osteoporosis have also been shown to have lower levels of plasma 
dietary and endogenous antioxidant vitamins (i.e., vitamins C, E, and A) and the lower 
enzymatic activities of superoxide dismutase and glutathione peroxidase when compared to 
healthy controls[27].  The alkalizing, antioxidant and anti-inflammatory properties of fruits and 
vegetables are just a few mechanisms by which bioactive food components may play a protective 
role in preventing bone loss.   
Among the fruits, mangos (Mangifera indica L) are an excellent source of vitamin C, and 
carotenoids, and are good sources of dietary fiber, potassium, copper, and vitamin K [28].  
Mangos also contain minerals such as magnesium, zinc, copper, manganese, and selenium [29].  
Mangos contain carotenoids, triterpenes, and phenolic compounds such as tannins, mangiferin 
and flavonoids which may contribute to its antioxidant and anti-inflammatory properties.  
Considering the bioactive compounds found in mango, it is hypothesized that mango may offer 
some dietary support in preventing and reversing hormone-related bone loss.   
The objective of this study is to determine if the addition of 5% or 25% freeze-dried 
mango powder to the daily diet would reverse bone loss in ovariectomized mice.  Our null 
hypotheses are that:    
1) Mango supplementation will not reverse the loss of bone mineral content (BMC) and bone 
mineral density (BMD) due to ovariectomy;  
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2) Trabecular and cortical bone micro-architectural parameters, assessed using micro-computed 
tomography analyses (µCT), will not be affected by mango supplementation;  
3) Bone strength, assessed using finite element analysis, will not be increased by mango 
supplementation; and 
4) Biomarkers of bone formation (i.e., plasma N-terminal propeptide of procollagen type 1 
(PINP)) and bone resorption (i.e., plasma pyridinoline (PYD)) will not be affected by mango 
supplementation.   
Identifying dietary factors that can reverse bone loss in experimental animals would 
establish a strong scientific framework for subsequent clinical trials in humans.  The findings of 
this proposed study will enable us to investigate the efficacy of mango as a novel nutritional 
strategy to reverse osteoporosis. Furthermore, this study will provide fundamental knowledge 
related to the health benefits of mango on body composition.  Findings of this study will provide 
a basis for consuming fruits to help combat postmenopausal bone loss.  If mango treatment 
shows effectiveness in reversing bone loss, these findings could potentially help the nation save 
millions of dollars spent on the treatment of osteoporotic fractures and bone-protecting 
pharmaceuticals.    
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
Prevalence of Osteoporosis   
By 2020, it is forecasted that there will be over 47 million cases of low bone density in 
the US and 14 million cases of osteoporosis [1].  In the US, $17 billion was spent on over 2 
million fractures in 2005. The majority of these fractures occurred in individuals over 65 years of 
age.  Seventy three percent of these fractures were non-vertebral fractures and accounted for the 
majority of the cost expenditure. By 2025, annual fractures are projected to increase by 50% with 
an estimated cost of $25 billion [30].  The increase in the number of hip fractures per year over the 
past 30 years is partly attributed to the increase in lifespan [31].  
Age is not the only important osteoporotic risk factor to consider.  Gender and ethnicity 
also influence bone density.  Osteoporotic fractures affect 1 in 3 women and 1 in 5 men over the 
age of 50 [3, 32].  In the US, over half of all postmenopausal Caucasian women are considered 
osteopenic with an additional 30% having osteoporosis [3].  The tendency for fracture is higher in 
the US Caucasian population and lower for other ethnic groups [33].  By the age of 80, up to 70% 
of white women have osteoporosis and 27% are considered osteopenic [3].  Cauley and 
colleagues[34] reported that Caucasian women are twice as likely to have hip BMD loss when 
compared to African-American women with an increase in hip BMD loss with age in both 
groups. 
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Bone Remodeling  
 Bone remodeling occurs as a continuous bone renewal process throughout the life span.  
In the bone remodeling process, old weakened bone is replaced by mechanically strong bone.  A 
healthy balance is maintained between bone formation and bone resorption.  Bone resorbing 
cells, known as osteoclasts (OC), and bone forming cells, known as osteoblasts (OB), work 
interdependently in the bone remodeling process [35].  With hormonal and cytokine signaling, 
OCs degrade bone to liberate mineral ions such as calcium and phosphorous needed by the body 
to replace old or damaged bone cells.  The OC creates an acidic environment with proton pumps 
and uses enzymes such as tartrate-resistant acid phosphatase and cathepsin K to catabolize the 
bone matrix minerals and organic components forming resorption pits known as Howship’s 
lacunae[36].  When the resorption phase is complete, the OC under goes apoptosis.  Initiating the 
bone renewal phase are coupling factors such as bone morphogenetic proteins, transforming 
growth factor-β (TFG-β), insulin like growth factor (IGF)-I and II, platelet derived growth 
factors and fibroblast growth factor that signal OBs and OB precursor cells to the Howship’s 
lacunae[37].  The OBs then synthesizes the organic bone matrix by secreting osteoid and regulate 
its mineralization by secreting matrix vesicles which concentrate calcium and phosphorous ions 
and enzymatically degrade inhibitors of mineralization such as pyrophosphate and 
proteoglycans[38].  As bone renewal process terminates, OBs can undergo apoptosis, become 
entombed in the bone matrix and become osteocytes, or become bone-lining cells.  When the 
balance between the bone remodeling of OCs and OBs is uncoupled in favor of bone resorption 
and osteoclastogenesis, osteopenia or osteoporosis may develop, weakening the bone, and hence, 
predisposing it to an increased risk for fracture [35].   
 
8 
Osteoblasts and Osteocytes 
Bone formation can be categorized in 3 stages; OB proliferation, extracellular matrix 
development and maturation, and mineralization [39].  Identification of the bone formation stages 
can be determined by serum biomarkers. For example, alkaline phosphatase and parathyroid 
hormone 1 receptor (PTH1R) are considered early markers of OB proliferation stage, while 
serum procollagen I N-terminal propeptide (PINP) and osteocalcin are considered marker of 
extracellular matrix development and bone mineralization, respectively[40].   
For bone formation to occur, OBs need to develop and mature before they can participate 
in the bone building process.  Mesenchymal stem cells in the bone marrow develop in to 
progenitor cells which may become adipocytes, myocytes, chondrocytes, fibroblasts, stromal 
cells or OBs.  The canonical Wnt/β-catenin pathway indirectly mediates the initial cascade of 
gene expression for skeletal development, bone formation and OB differentiation.  Wnt10b shifts 
the mesecnchymal stem cells fate to the OB lineage by suppressing adipogenic transcription 
factors and inducing osteogenic transcription factors such as the runt-related transcription factor 
2 (Runx2), D1x5 and Osterix [39, 41].  These pathways are induced in response to extra cellular 
stimuli such as bone morphogenetic proteins, growth factors, hormones, cytokines, matrix 
proteins, transcription factors, regulatory co-factors and environmental stress [39].  
An active osteoblast is distinguishable by its large nucleus and golgi apparatus, well 
developed endoplasmic reticulum, and high concentration of alkaline phosphatase enzyme 
activity in the proliferation stage[40].  OBs are anabolic to bone and function by developing the 
extracellular bone matrix and directing its mineralization.  The OBs secrete a fibrous, non-
mineralized protein substance known as osteoid, which contains chondroitin sulfate, osteocalcin 
and type I collagen and forms the bone matrix.  Osteocalcin, osteopontin and bone sialoprotein, 
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also secreted by the OB, serve to mineralize the extracellular matrix, by binding calcium and 
phosphates, and regulates both the amount and size of hydroxyapatite crystals in bone [39]. 
OBs, at the terminal differentiation stage, may develop into osteocytes.  Osteocytes are 
bone cells found throughout the bone matrix which support the structure and metabolic functions 
of bone [39].  The cellular connection within the bone plays an important role in building strong 
bones.  Cell-to-cell and cell-to-matrix interactions are maintained by adhesion and trans-
membrane proteins.  Surface lining bone cells, which are composed of flattened inactive OBs, 
separate the bone from the marrow[39].  Communication exists between the lining cells and the 
OBs via adherens junctions.  In these junctions are cadherins, calcium dependent trans-
membrane proteins, which assist in anchoring the surface lining and OB cells through their 
cytoskeleton [39].  N-cadherin, mediated by bone morphogenetic protein (BMP)2, functions in 
cell-cell adhesion [39].  These type of cell-cell interactions encourage osteoprogenitor 
differentiation and OB survival[42].  Integrin, an adhesion protein, joins the bone’s extracellular 
matrix to the structural proteins in the cytoskeleton, and induces OB differentiation, through the 
mitogen-activated protein kinase (MAPK) pathway[39].  Connexins, integral membrane proteins 
at gap junctions, allow the osteocytes to communicate with each other in response to mechano-
stimulation.  Mechano-sensory information stimulates signaling pathways for OB gene 
transcription.   
 
Osteoclasts 
The bone resorbing OCs are also formed in the bone marrow, but from a monocyte-
macrophage myeloid lineage of hemopoietic stem cells [43].  OCs not only function in bone 
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degradation, but also as immunomodulators in pathological conditions and may also regulate OB 
function [44].   
Cytokines, receptor activator of nuclear factor-kB ligand (RANKL), macrophage colony 
stimulating factor (M-CSF), and c-Fos, a RANKL activated transcription factor, are necessary 
for OC differentiation [45].  Both RANKL and M-CSF are produced by bone marrow stromal 
cells, OBs, T lymphocytes and synovial fibroblasts[46].  RANKL can also be found in other 
tissues such as in the lymph nodes, thymus gland, lungs, spleen, mammary epithelial cells and in 
some cancer cells [47].  RANKL is a member of the tumor necrosis super family of proteins and is 
essential for OC formation.  M-CSF contributes to OC precursor differentiation, proliferation, 
and survival.  Osteoclastogenesis can be detected by tartrate-resistant acid phosphatase (TRAP) 
and proteinase cathepsin K enzyme activity, wich appear 3-5 days after differentiation [48, 49].  
Mature OCs can be identified by its large size, approximately 40 micrometer in diameter, 
multiple nuclei, resulting from cytoplasmic fusion of the precursor monocytes, a "foamy" 
cytoplasm appearance and extensive golgi complex [50].   
OCs attach at resorption sites via actin-rich podosomes securing a tight seal on bone [51].  
Integrins act as receptors allowing the OC to bind to the bonding sites in the bone via 
osteopontin and virtonectin glycoproteins [52].  Approximately 10 – 14 days after OCs attachment 
to bone, OCs create a pocket which is acidified by a proton pump and a chlorine channel [39].  
Hydrochloric acid and proteases degrade the bone matrix while the lysosomal enzyme, cathepsin 
K, breaks down the mobilized type 1 collagen [39, 48, 50]. 
The RANKL signaling pathway plays an important role in bone resorption.  RANKL, a 
transmembrane protein on the osteoblast, binds to receptor activator of nuclear factor-kB, 
RANK, on the OC precursor and OC, increasing OC formation, activity, and bone resoption.   
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OPG functions to protect bone from breakdown by intercepting RANKL, reducing the 
rate of OC formation, activity and bone resorption [53] (Figure 1).  OPG expression is regulated 
by WNT/β-catenin signaling in OBs [54] and it  also expressed in other tissues aside from OBs.  
Pro-inflammatory cytokines up-regulate RANKL while suppressing the expression of OPG[46].   
RANKL stimulates osteoclastogenesis by activating multiple signaling pathways 
encoding for TRAP, cathepsin K, the calcitonin receptor and β3-integrin[46].  One influential 
signaling pathway induces long lasting oscillations of intracellular Ca2+ concentration while 
generating reactive oxygen species (ROS) (Figure 2).  RANKL mediates stimulation of Rac1, 
which generates ROS that trigger phospholipase Cγ1 to initiate the Ca2+ oscillations.  Btk kinase 
activates phospholipase Cγ1 (PLCγ1), tumor necrosis receptor activator factor 6 (TRAF6), and c-
Fos (transcription factor).  The Ca2+ oscillations then activates calcineurin and nuclear factor of 
activated T-cells c1 (NFATc1) to stimulate osteoclastogenesis [55] (Figures 1 & 2).  The role of 
TRAF6, c-Fos and NFATc1 in the OC precursor nucleus are put in the perspective of the bone 
remodeling cycle in Figures 1 and 2. 
 
Figure 1: Ostoclastogenesis regulation via the receptor activator of nuclear factor-kB ligand 
(RANKL) signaling pathway [50] 
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Figure 2: NFATc1 signaling in osteoclastogenesis via ROS and Ca2+ oscillations [50] 
 
Factors Affecting Bone Remodeling  
The bone remodeling process is regulated by multiple factors.  Genetics influence bone 
remodeling as well as hormones, growth factors and locally produced cytokines [56].  Lifestyle 
factors such as amount of weight bearing exercise, nutritional status, smoking, alcohol 
consumption and caffeine intake also affect the bone remodeling process.  A disturbance or 
change in any of the bone regulatory factors can contribute to an uncoupling of the bone 
remodeling process which can lead to osteoporosis.   
 
Genetics 
 Genetics play an important role in regulating peak bone mass.  Up to 60 -80% of 
variance in peak bone mass between individuals can be attributed to genetics [56].  Although both 
elderly men and women lose bone with increasing age, postmenopausal women lose more bone 
than men [57].  The risk for fracture is doubled in women when compared to men of similar age 
[57]
.  Ethnicity also influences BMD and fracture risk.  The incidence of reported hip fractures is 
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lower in Asian than Caucasian populations [58].  Women also vary in terms of the rate and extent 
of postmenopausal bone loss, some considered fast or slow losers. This variance is in part due to 
inherited factors.  In observational studies, associations between family history of fracture 
incidence and type of fracture have suggested an inherited correlation in BMD and fracture risk 
[59-61]
.  In human and animal studies, high levels of heritability have been shown in bone 
phenotype as assessed by bone densitometry and ultrasound [62, 63].  Allelic variation in the 
vitamin D receptor, has shown to influence genetic determination of bone phenotype.  The 
impact of the vitamin D receptor can be mediated by body size and development and by 
hormonal regulation.  Intronic polymorphisms of the collagen Iα1 gene have been related to 
BMD and fracture risk[57].  Allelic variations in the estrogen receptor, TGFß receptor, TGFß1, 
insulin-like growth factor-I pathway, IL-4, IL-6, calcitonin, PTHRs and for apolipoprotein E 
have all been associated with BMD phenotypes [57].  Hormonal factors, nutrition and lifestyle 
interact with genetic factors over time. 
 
Hormones  
Sex steroids, PTH, thyroid hormones, growth hormone, glucocorticoids, and 
1,25(OH)2D3  influence the bone remodeling process[64].  Estrogen, have an inhibitory effect on 
osteoclast function by promoting osteoclast apoptosis [65] and by modulating osteoclast 
differentiation [66].  Estrogen also decreases the OB progenitor cell population but exerts an 
anabolic influence on OBs.   
PTH plays a dual role in the bone remodeling process.  On one hand, PTH and 
1,25(OH)2D3  encourage bone remodeling by increasing the expression of  NF- kB, tumor 
necrosis factor (TNF), RANK, RANKL, and M-CSF [67].  On the other hand, PTH, IGF and other 
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growth factors stimulate mesenchymal stem cell, osteoprogenitor and osteoblast differentiation.  
The cell membrane of the parathyroid gland has calcium sensing receptors which regulate PTH 
secretion.  Low serum calcium signals the parathyroid gland to secrete more PTH which 
enhances renal tubule reabsorption of calcium, increases bone resorption, and increases intestinal 
calcium absorption indirectly by increasing 1α, 25(OH)2 D3  synthesis in the kidneys [68]. 
Calcitonin is a peptide hormone produced by the C cells of the thyroid gland which acts 
to lower blood calcium levels when they are too high by inhibiting bone resorption [69].  The 
secretion of calcitonin is regulated by serum calcium, gender and age [70, 71].  Calcitonin has been 
manufactured as a pharmaceutical to inhibit osteoclast bone resorption and hypercalcemia [70].  
The metabolic hormone, insulin, also regulates bone remodeling.  Insulin signaling 
activates osteoblasts and enhances osteocalcin production[72].  Osteocalcin facilitates bone 
mineralization and calcium ion homeostasis.  Osteocalcin also impacts glucose homeostasis via 
its interaction with OCs  [72].  With the acidic OC environment, osteocalcin, secreted by the 
osteoblast, is decarboxylated to its active form [72].  Osteocalcin, in turn, mediates insulin 
secretion and sensitivity (Figure 3).  Ferron and colleagues (2010)[72] demonstrated that insulin 
signaling in osteoblasts is a critical link between bone remodeling and energy metabolism. 
Figure 3:  Insulin signaling and bone remodeling [72] 
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Leptin, a cytokine-like hormone secreted by adipose tissue, also influences bone 
remodeling via hypothalamic mediation of the sympathetic nervous system [73].  Leptin has an 
anabolic effect on osteoblasts and stimulates bone growth indirectly via the central nervous 
system.  Leptin stimulates the growth hormone/ insulin-like growth factor-1 (GH-IGF-1) axis of 
the central nervous system and suppresses release of neuropeptide Y, an inhibitor of cortical 
bone formation, from the hypothalamus. The GH-IGF-1 axis stimulation impacts both β1 and β2- 
adrenergic receptors (Figure 4).  Although β2- adrenergic stimulation encourages trabecular 
bone remodeling, β1- adrenergic stimulation increases cortical bone mass.  Cortical bone 
becomes more important when dealing with the excess weight load from increasing amounts of 
adipose tissue.   A study done on leptin deficient mice showed that, not only are leptin deficient 
mice obese with symptoms of metabolic syndrome, but they also exhibited skeletal 
abnormalities[74].  Leptin repletion enhanced normal bone growth by increasing femoral length 
and total bone volume although femoral and vertebral cancellous bone volume decreased [74].   
Figure 4 :  Leptin’s influence on bone [75] 
 
[73]
 
Ct = cortical bone,;Tb = trabecular bone; GH = growth hormone;  AdrB1= adrenergic receptor 
β1;  AdrB2 = adrenergic receptor β2; IGF-1= Insulin like growth factor 1  
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Cytokines involved in Ovarian Hormone Deficiency  
Local cytokines also influence bone remodeling.  Immune and bone marrow cells 
synthesize and secrete cytokines that may have autocrine and paracrine influences on bone 
metabolism [76, 77].  With lack of estrogen regulation, caused by natural or surgically induced 
menopause, blood, bone marrow, and monocytic levels of IL-1, IL-6, TNF-α, and the related 
factors IL-1ra and IL-6R increase [78].  IL-1 and TNF activate OCs indirectly by influencing OB 
secretory factors such as RANKL and inhibit OC apoptosis.  They also enhance OC formation by 
stimulating the proliferation of the OC precursors and stromal cells by activating IL-6, M-CSF, 
and granulocyte M-CSF [78]. 
 
 
Lifestyle factors  
Nutrition 
Nutrition is an important determinant of bone health, yet the effects of nutrients and 
minerals other than calcium involved in the bone remodeling process are still being elucidated.  
Bone formation requires adequate supplies of energy, amino acids, and bone-forming minerals 
such as calcium, phosphorus, magnesium, and zinc.   
Adequate amounts of protein are necessary to prevent the development of osteoporosis 
[79]
.  Sufficient protein intakes reduced bone loss and fracture risk in the elderly [80]. Excess 
protein above the recommended allowances, however, can create renal acid load and lead to risks 
of developing osteoporosis [81].  Excessive renal acid load may be more influential on bone size 
and mass rather than volumetric bone density  [82].   
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Consuming an alkaline diet may have bone protective effects.  Protons are produced 
during metabolism and are neutralized by the buffering action of anions generated from food or 
liberated from bone [83].  Since increases in bone resorption lead to greater urinary calcium 
excretion, a high renal acid load could potentially be associated with increased bone loss in older 
adults [84].  Foods with a high acid load are those rich in sulfur amino acids, phosphorous or 
chloride, such as meat, grains, nuts, and dairy products.  Alkaline foods are those rich in 
potassium and magnesium salts of organic acids, as is the case with fruits and vegetables. 
Considering this information, fruits such as mango, may play a role in maintaining bone health.   
Calcium, vitamins D, K, and C, magnesium, boron, copper, fluoride, manganese, 
potassium, silicon, zinc, and isoflavones are dietary factors contributing to bone formation [29, 85, 
86]
.  Copper, manganese, carbonate, citrate and vitamins C, D and K are involved in crystal and 
collagen formation, cartilage and bone metabolism and/or the calcium and phosphorus 
homeostasis [86]. Zinc, copper, iron and manganese are essential cofactors for enzymes involved 
in the synthesis of the bone matrix [87].  Studies have shown that intake of these minerals has been 
positively associated with bone mass, while deficiency has been correlated either with reduced 
bone mass or slow fracture healing [88].  Evidence over the last 30 years strongly suggests that 
silicon is beneficial to bone and connective tissue health including the synthesis of collagen 
and/or its stabilization, and bone matrix mineralization [88].  In a human osteoblast cell culture 
study, vitamin K2 enhanced osteocalcin production, induced by 1,25(OH)2D3 [89]  and the 
accumulation of γ-carboxyglutamic acid containing osteocalcin [89] .  A type of vitamin K2, 
addressed as K2-7, also demonstrated an anabolic effect on bone tissue in osteoblastic (MC3T3-
E1) cells [90].  In addition to vitamin K2 stimulating OB and osteocalcin production, vitamin K2 
has also been shown to attenuate OC formation and activity in rat bone cells in vitro [91]. 
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It is important to maintain adequate calcium intakes throughout life.  Calcium helps to 
optimize bone formation during growth and minimizes bone loss in later life.  Ninety nine 
percent of the human body’s calcium is stored in the bone as hydroxyapatite.  Hydroxyapatite 
bone crystals are comprised in a ratio of 2:1 calcium to phosphate with trace amounts of other 
minerals.  The hydroxyapatite crystals contribute to the weight bearing and mechanical 
properties of the bone which can also be mobilized through bone remodeling to meet other 
biological functions of calcium and phosphorous in the body [68].  According to a meta-analysis 
[92]
, every 300 mg increase in calcium intake has been associated with a 4% decrease of fracture 
risk in postmenopausal women.  Another meta-analysis study of randomized controlled trials on 
post menopausal women showed a 2.02% reduction in bone loss with calcium supplementation 
of at least 400 mg/day over a two year period [93].   
Calcium in the blood is found in the form of free ions or bound to albumin, globulin or 
phosphate, citrate or other anions. Intracellular calcium concentrations are about 10,000 times 
less than extracellular concentrations.  Calcium increases bone strength by being a principal 
component of mineralized bone and by reducing serum PTH which lowers bone turnover rate.  In 
addition to building bone, calcium also is involved in blood clotting and intracellular adhesion.  
Calcium also acts as a signal transducer in muscle contraction, hormone secretion, kinase 
phosphorylation, neurotransmitter release, vision, glycogen metabolism, cellular differentiation, 
proliferation and motility [68].   
Calcium concentration in the blood is regulated with strict control by parathyroid 
hormone (PTH) and vitamin D at 2.5 mM/L (Figure 5).  BMC is sacrificed at the expense of 
maintaining serum calcium ion concentrations.  Low serum calcium and phosphorous levels 
increase PTH production.  PTH encourages bone resorption and encourages renal tubule calcium 
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re-absorption by converting vitamin D to its active form (Figure 5) to meet serum calcium 
needs.  Vitamin D increases calcium absorption in the intestines and reabsortion in the kidneys.  
1,25(OH)2 vitamin D3  interacts with vitamin D receptor in the enterocyte and stimulates the 
synthesis of calcium-binding protein.  Calcium receptors are located in the intestine, osteoblast 
cell lines, calcitionin secreting c-cells of the thyroid gland, parthyroid gland, and the  1,25(OH)2 
vitamin D3  producing cells of the renal proximal tubule [94]. Low blood calcium status increases 
calcium absorption in the intestine.  However, chronic low calcium intake will lead to increased 
bone resorption due to increase in PTH.[71]. 
Figure 5:  Bone Metabolism[95] 
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Adequate calcium intake for postmenopausal women is 1200 mg/day with most women 
falling short in meeting this requirement through diet alone[96].  Intestinal calcium absorption 
declines with age or when calcium intake is high.  Calcium absorption is more efficient if 
calcium is consumed in amount spread throughout the day rather than consuming it all at once.  
Calcium bioavailability needs to be considered when choosing calcium food sources.  Calcium 
absorption from diet is between 20% and 60 % [71]. Calcium is absorbed more easily when it can 
disassociate more readily from its ligands.  However, low molecular weight calcium salts can be 
absorbed intact without a vitamin D induced calcium transporter.  Enhancers of calcium 
absorption are soluble salts that prevent precipitation of calcium by phosphates (i.e. calcium 
citrate malate), inulin and fructooligosaccharides.  Some casein and whey peptides also prevent 
precipitation of calcium by phosphates.  Inhibitors to calcium absorption are oxalate and phytic 
acid[71].   
In addition to assuring adequate calcium intake it is also important to consider calcium 
losses through the urine.  Urinary excretion impacts calcium retention by about 50% [97].  
However, increases in dietary calcium only affect urinary output of calcium by approximately 
6% while dietary sodium exerts a much greater effect on urinary calcium excretion and 
contributes to low BMD in postmenopausal women [97]. Although high protein intake increases 
urinary calcium excretion, net calcium retention is not affected because of changes in calcium 
absorption and endogenous calcium secretion [98].  Urinary calcium tests are not done routinely 
but conducted to determine the etiology of kidney stones or to check for problems with the 
parathyroid gland[99].  In addition to low calcium having a negative impact on BMD, low 
extracellular calcium also increases the risk for hypertension, preeclampsia, premenstrual 
syndrome, obesity, polycystic ovary syndrome and hyperparathyroidism [68]. 
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Vitamin D is involved in bone formation by regulating calcium and phosphorous amounts 
in the blood and by promoting bone mineralization.  Indirectly, vitamin D is involved in bone 
remodeling by its role in differentiation and proliferation of hematopoietic cells, keratinocytes, 
parathyroid secreting cells and beta cells of the pancreas [68].  Vitamin D must be metabolized by 
both the liver and kidney before becoming biologically active as a steroid hormone.  The active 
metabolite 1α, 25(OH)2 vitamin D3 functions as a steroid hormone by generating biological 
responses via regulation of gene transcription and activation of signal transduction pathways [68, 
100]
 .  The other kidney metabolite of vitamin D, 24R,25 (OH)2D3 has been shown to improve 
bone fracture healing in chickens  [24].  In the intestine, vitamin D assists with calcium, 
magnesium and phosphorous absorption [101] (Figure 5).  Vitamin D receptors are both nuclear 
and membrane specific and are close to plasma membrane as well as found in bone and bone 
marrow.  Vitamin D participates in bone remodeling through its involvement in OB 
differentiation, inhibiting OB apoptosis, encouraging calcium mobilization, and inducing 
osteocalcin production [101].  When plasma calcium and phosphorous levels are low, the kidneys 
convert 25(OH) vitamin D3 to 1α, 25(OH)2 vitamin D3, its active steroid hormone form..   The 
enzyme 1α, 25-hydroxylase is an important regulator of the active metabolite of vitamin D 
production in the kidneys.  It is regulated by 1α, 25(OH)2 vitamin D3 concentrations, serum 
calcium and phosphate levels and PTH.  The enzyme 1α, 25-hydroxylase is also iron dependent.  
Therefore, variations in iron levels indirectly affect bone by decreasing 1α,25(OH)2 vitamin D3  
production.   
Optimal health may require a vitamin D status much greater >25 nmol/L, the threshold 
for 25-hydroxyvitamin D set to avoid clinical deficiency[102].  The RDA for elderly females is 
600 IU/day (10-15 µg/day) [2].  Aside from dietary sources, the skin produces a precursor to the 
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active vitamin D when the sun’s ultraviolet rays transform 7-dehydrocholesterol into 
cholecalciferol.  Cholecalciferol is hydroxylated in the liver to form 25-hydroxycholecalciferol, 
also known as calcidiol, which is stored in the liver until needed.  When needed, calcidiol is 
hydroxylated to its biologically active form, calcitriol, in the kidney.  Minimum levels ranging 
from 25 nmol/L to >100 nmol/L have been proposed, largely due to the inverse relationship of 
25(OH)D3 (calcidiol) and PTH.  High PTH is a risk factor for osteoporosis in older adults[102].  
An estimated 80% of elderly postmenopausal women may have vitamin D deficiency, defined by 
levels less than 20 ng/mL or 50 nmol/L [103].  Production of vitamin D binding protein, which is 
responsible for vitamin D (calcitriol) transport in the blood, increases by 50% in high estrogen 
states [68]. 
Vitamin C, present in high amounts in mango, plays a critical role in collagen synthesis.  
Collagen is necessary for bone, skin and tendon formation.  Vitamin C is a cofactor which 
promotes enzyme activity by maintaining metal ions in their reduced form.  It is involved in the 
hydroxylation of proline and lysine residues which form the cross linking necessary to form the 
triple helical structure of collagen.  More specifically, α-ketoglutarate-dependant dioxygenases 
incorporate one atom of oxygen into succinate and into the oxidized product in the presence of 
ferrous iron [68].  Ascorbic acid stimulated collagen production in vitro fibroblast cells by 60-
100% [104].  A study analyzing the effects of vitamin C supplementation (745 mg/day) on BMD 
of postmenopausal women, demonstrated that vitamin C users had BMD levels that were 3% 
higher at the midshaft radius, femoral neck, and total hip than non-users[105].  Women taking both 
estrogen and vitamin C had significantly higher BMD levels at all sites. Women who took 
vitamin C plus calcium and estrogen had the highest BMD at the femoral neck, total hip, 
ultradistal radius, and lumbar spine [105]. 
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The phytonutrients found in fruits and vegetables may play an important role in 
modulating bone metabolism without the side effects associated with pharmaceutical 
interventions.  Phytonutrients, such as phenolics, may function as antioxidants, donating 
hydrogen ions, scavenging free radicals, inhibiting radical generation, inhibiting enzyme activity 
or by specific receptor interactions[19].  Antioxidant functions include enzyme inhibition, metal 
chelation, hydrogen donation and by oxidizing non-propagating radicals[19].  Phenolics can 
inhibit xanthine oxidase and other enzymes involved in the production of ROS[19].  They can also 
function as anti-inflammatory agents by inhibiting lipoxygenase, the enzyme responsible for 
creating prostaglandins and leucotrienes from arachidonic acid[106].  Some phenolics modulate 
signal transduction by inhibiting tyrosine kinase[19].  Some flavonoids and isoflavonoids inhibit 
17 β – hydroxysteroid oxidoreductase which may influence sex hormone metabolism[107].   
Population studies show a positive correlation with fruit and vegetable intake and BMD 
[25], 109[13, 18, 108].
  For example, women who consumed vegetables more than 9 times a week had 
higher BMD compared to those with lower intakes [109].  Higher BMD was observed at the heel 
site of women consuming more than 1.5 servings of vegetables a day in a study on a rural 
population in Iran [108].  The benefits of fruits and vegetables results from an additive and 
synergistic effect from the combination of phytochemicals[25].  The antioxidant action of the 
phytonutrients may be responsible for these findings and for this reason it is important to 
consider the oxidative status associated with osteoporosis. 
Oxidative stress is considered as an independent risk factor for osteoporosis[110].  
Increased OC activity and decreased OB activity have been associated with an imbalance 
between oxidant and antioxidant status in postmenopausal osteoporosis[111].  When bone 
remodeling is imbalanced, as in osteoporosis, ROS production by the OC may overwhelm the 
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body’s endogenous antioxidants defense mechanisms leading to further bone loss.  Enhanced OC 
activity increases superoxide anion generation and inhibits superoxide dismutase and glutathione 
peroxidase activities[112].  In murine models, superoxide anion was proposed to oxidize calcium 
binding sites and/or acidify the local environment near OCs, favoring bone loss[113].  
Transcription factors, such as nuclear factor-kB (NF-kB) which signals TNF production and 
inflammation, are sensitive to oxidative changes[19].  Basu and colleagues established a 
biochemical link between increased oxidative stress and reduced bone density by showing 
elevated oxidative stress marker 8-iso-prostaglandin F2α and elevated inflammatory marker 15-
keto-13,14-dihydro-prostaglandin F2α  in osteoporotic subjects when compared to those without 
osteoporosis[114, 115].  Hence, antioxidant supplementation has been proposed as a novel 
therapeutic strategy for osteoporosis. 
Phytonutrients have been shown to play a protective role in preserving BMD in animals 
[14, 15, 20, 116, 117]
 and in vitro [16, 118-120].  Orange pulp and citrus fruits in general contain high 
amounts of vitamin C and flavonoids and have shown to improve bone density in male 
orchidectomized rats [14, 15].  Citrus hesperidin and olive oleuropein together, were also shown to 
prevent bone loss and improve peek bone mass in female rats [117].  Green tea polyphenols 
reduced the extent of bone micro-architecture deterioration in female rats [116].  Pholridzin in 
apples, rutin, and isoflavones have all been shown to prevent bone loss in ovariectomized rats 
[20]
.  Flavonoids, quercetin and kaempferol was shown to inhibit bone resorption in vitro [118].  
Antioxidants present in fruits and vegetables may reduce oxidative stress in the bone 
environment by reducing OC differentiation.  For example α-lipoic acid was able to inhibit OC 
differentiation [121], while lycopene was shown to reduce oxidative stress and bone turnover 
markers in postmenopausal women[122].  Dried plum polyphenols inhibited osteoclastogenesis by 
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down regulating NFATc1 and inflammatory mediators and attenuated TNF-α on osteoblast 
function with upregulation of Runx2, Osterix and IGF-1 in MC3T3-E1 cells and in gonadal 
hormone deficient, inflammation induced animal model [16, 119, 120].   
 
Lifestyle Influences on Bone  
Weight-bearing exercise exerts a mechanical stimulation on bone tissue.  Resistance and 
high-impact activities contribute to development of peak bone mass and may reduce risk of falls 
in older individuals [2].  Many studies have confirmed bone loss resulting from immobilization 
and micro-gravity in both animals and humans [123-125].  Studies with increased loading activity 
have resulted in increased bone mass often localized to the bones where the loading took place 
[126, 127]
.  Mechano-stimulation to the osetocytes creates a signaling pathway to generate more 
OBs.   
Current research indicates that smoking not only increases the risk for osteoporosis in 
women but also in men and adolescents [128].  Even second hand smoke has been correlated with 
an increased risk for osteoporosis and fracture according to a study done on Chinese men and 
pre-menopausal women [129].  Findings from this study showed that premenopausal women 
exposed to second- hand smoke had a “threefold higher risk of having osteoporosis and a 2.6 
times greater risk for a non-spine fracture” when a family member smoked [129].  Other studies 
show that second-hand smoke may alter estrogen levels thereby effecting health [128].  A study 
conducted on young Sweden men demonstrated that  24% of smokers had bone fractures 
compared to only 14% or those who never smoked [130, 131].  Moreover, smokers had lower bone 
density in the spine, hip, and whole body when compared to non-smoking peers [130, 131].  Overall, 
smoking can double osteoporosis risks in men [128].   
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Alcohol, consumed moderately, may provide benefits to the BMD of postmenopausal 
women [132, 133] and in men over age 45[133].  In contrast, studies done on alcoholics report lower 
bone mineral density[134, 135].  In the research conducted by Holrook and colleagues (1993), social 
drinking of up to 180 g/day of alcohol in men and 120 g/day in women  [133] resulted in an 
increase in BMD at the femoral neck of men and the spine of women in a one week study and in 
the radial shaft and spine of women in the 24 hour study [133].  Stronger associations on BMD 
were seen with beer or wine consumption compared to liquor consumption[132].  In men, 2 or 
more servings per day of liquor resulted in lower BMD [132]. This may suggests that constituents 
in the wine and beer, other than ethanol, may contribute to bone health. For example, the high 
silicon content of beer has been associated with increases in BMD [88, 132].   
The effects of caffeine on bone are inconclusive.  Some studies have shown detrimental 
effects of caffeine on bone, some of which have disappeared after making statistical adjustments 
for osteoporotic risk factors  [136].  A study conducted by Rapuri and colleagues (2001) [137] found 
that women who consumed more than 300 mg/day of caffeine had a significantly higher rate of 
bone loss in the spine.  In contrast, Japanese women who drank green tea regularly had 
significantly higher BMD than those who did not [138].  In addition to the observational findings 
correlating green tea and BMD, in inflammation induced rats, green tea polyphenols attenuated 
BMD loss [116] and in bone marrow mesenchymal stem cells green tea catechins encouraged 
osteogeneis [139]. The interaction of an individual’s genotype with caffeine may affect the BMD 
study outcomes with some caffeine metabolizing genotypes being more susceptible to bone loss 
than others [140].  This genotypic variation among individuals may help explain some of the 
controversies and inability of other studies to show clearly the effect of caffeine on bone. 
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Postmenopausal Osteoporosis 
Being postmenopausal or in a state of surgically-induced menopause increases bone 
resorption [2].  For the most part, this phenomenon is attributed to a decrease in estrogen 
production.  Estrogen production declines several years before the cessation of menstruation 
which typically occurs between 48 and 50 years of age [141].  Consequently, osteoporosis is most 
commonly found in the elderly female population.  Development of osteoporosis in women has 
also been associated with the time of menarche, menopause, and the duration of lactation [142].  Li 
and  Zhu (2005) [143] demonstrated that the later menarche, the earlier the menopause, the greater 
number of child births and the longer the duration of lactation all lead to lower BMD and a 
higher degree of osteoporosis. 
Estrogen has a protective influence on bone by attenuating OC proliferation and activity.  
Estrogen receptor α (ER α) is present on both the osteoprogenitor cells and the OCs.  When 17β-
estradiol binds to the ER α, it triggers apoptosis in the OC and inhibits OC differentiation in the 
progenitor cells[144].  With a dramatic decline in estrogen production during menopause, bone 
remodeling increases several fold.  Postmenopausal bone resorption doubles and biomarkers of 
bone formation are less than half the levels of that observed premenopause [145].   
Estrogen deficiency also increases FSH secretion which encourages the production of 
inflammatory cytokines, such as TNF-α and several ILs by bone marrow and immune cells. The 
cytokines, in turn, encourage OC differentiation.  The lack of estrogen stimulation during the 
postmenopausal state complemented with declined levels of GH which occurs with aging leads 
to weakened signaling on the OB (Figure 6). 
Estrogen not only exerts an influence on the OCs but also on the OBs.  Estrogen 
attenuates OB progenitor/ mesenchymal stem cell production by as much as 50% [146].  In the low 
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estrogen environment post menopause, there is an increase in OB progenitor production.  OB 
progenitors are not only involved in OB formation but also the formation of adipocytes, 
chondroblasts, myoblasts and fibroblasts and play an important role in OC signaling [146].  With 
aging, OB progenitors preferentially differentiate into adipocytes rather than OB[147] which may 
also help explain the tendency for increased adiposity post menopause.  Although lack of 
estrogen increases the rate of formation of the OB progenitors, the rate of production is not 
sufficient enough to counter the increased rate of bone remodeling.  
 
Figure 6:  Hormonal stimulation on OCs and OBs [148]. 
                                        
*Lack of estrogen represented by        and estrogen stimulation represented by 
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Although estrogen modulates OB progenitor production, it still exhibits an anabolic effect 
on OBs.  Estrogen encourages OB differentiation, proliferation and increases OB proteins such 
IGF-1, type I procollagen, transforming growth factor beta (TGF-β) and BMP [141].  Estrogen 
also inhibits OB and osteocyte apoptosis [149].  Estrogen suppresses bone resorption by increasing 
OC apoptosis [150] increasing OPG production and decreasing OB/stromal cell production of 
RANKL[151].  The activation of the Src/Shc/ERK–signaling pathway influences the estrogen 
receptors in the OB lineage of cells to prevent apoptosis of OB cells [152].  A decrease in the 
number of cells that support osteoclast development, together with decreased production of 
osteoclastogenic cytokines by these same cells may be responsible for the potent suppression of 
osteoclastogenesis by estrogens [146].   
Estrogen also increases nitric oxide (NO) and TGF-β levels.  An appropriate level of NO 
is necessary to protect bones and organs from ischemic damage while chronically high levels of 
NO can cause tissue toxicity, inflammation and carcinomas [153].  NO and TGF-β regulate T cell 
production of TNF-α and act to inhibit osteoclastogenesis and bone resorption [6].  Estrogen 
deficiency in postmenopausal women is associated with an increase in pro-inflammatory 
cytokine production such as IL-1, TNF- α, and IL-6 [4, 6] in the bone environment (Figure 6). 
These pro-inflammatory cytokines are involved in osteoclastogenesis and encourage bone 
resorption [7]. The inflammatory cytokines also produce oxygen free radicals which contribute to 
osteoclast formation, differentiation and activation (Figures 1 & 2).  IL-1 and IL-6 also increase 
the production of M-CSF which further influences OC differentiation.  Estrogen also regulates 
the release of growth factors and growth hormones such as TGF-β and IGF-I [154].   
In addition to the menopausal effects on OB progenitors, OBs, and OCs, estrogen 
deficiency also affects calcium balance.  In an estrogen deficient state, intestinal calcium 
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absorption is decreased while urinary calcium loss is increased [155].  Intestinal mucosal cells 
have receptors for 17β-estradiol which increase calcium transport/absorption [156].  The kidneys 
also reabsorb calcium better when estrogen is present [157].  This is attributed to an increase in 
circulating 1,25-(OH)2D3 which is indirectly mediated through stimulation of renal la-
hydroxylase by increased serum PTH[158]. In addition to the direct effects of estrogen on calcium 
absorption, there is also reduced total circulating concentration of 1,25(OH)2D3  as one ages, 
which effects both calcium absorption and, indirectly, bone formation.   
Estrogen receptors α and β are activated by 17β-estradiol and function as a DNA binding 
transcription factor.  In the absence of estrogen, the inactive α receptor located on the nucleus is 
associated with several heat shock proteins [159].  In the presence of a receptor stimulus, like 17β-
estradiol, the receptor undergoes a conformational change displacing the inhibitory heat shock 
proteins and forms dimers. The dimers allow the receptor to interact with “specific steroid 
response elements (SRE) located within the regulatory regions of target promoters [160].  The 
ligand-activated receptor can interact with the general transcription apparatus (GTA) directly or 
indirectly through adaptor proteins. Ultimately, these interactions stabilize the transcription 
preinitiation complex and enhance RNA polymerase activity [160] . 
Bone also degrades with age and can be attributed to the degree of mineralization, 
anisotropy, skeletal geometry and the periosteal response to trabecular bone mass [161].  Growth 
hormone secretion declines 14% per decade and is one of the primary factors responsible for low 
serum IGF-I levels which are directly correlated with BMD [103].  Adrenal androgens, 
dehydroepiandrosterone (DHEA) and DHEA sulfate are also 10-20% lower than young adults 
further contributing to a lack of bone building stimulus factors[162].   
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Animal Model 
Laboratory animals have played a major role in understanding osteoporosis and 
developing treatment options for the management of osteoporosis[163].  The success of an animal 
model is based on its ability to successfully predict outcome measures in people.  Because the 
average life-span of the laboratory mouse is about 2 years, one year is roughly equivalent to 
middle age.  A menopausal state, however, can be induced surgically by ovariectomy [163].  
Ovariectomized mice are comparable to women who undergo bilateral ovariectomy prior to 
menopause and prematurely experiences menopausal symptoms soon after surgery [163].  Hence, 
the ovariectomized mouse experiences an increase in bone turn over, osteopenia and weight gain 
[163].
  It takes the mice 21 days post ovariectomy to reach a state similar to that of early 
menopause whereas after 35 days corresponds to late menopause in women[164].  Research 
conducted by Lynch and colleagues demonstrated that the mouse tibia did not experience 
significant bone loss or architectural adaptation following OVX in growing mice [165].  However, 
ovariectomy-induced estrogen deficiency resulted in a reduction in vertebral bone mass due to 
decreased trabecular thickness and increased separation when compared to SHAM control mice 
at 6 weeks post OVX in 26week old C57Bl/6 mice[166].  The decreases in bone mass did not 
affect mechanical integrity of lumbar vertebrae, suggesting that a duration longer than 6 weeks is 
needed before bone mass changes result in deterioration of mechanical properties[166].  Several 
studies have used the ovariectomized mouse model to study both nutrition and pharmaceuticals 
in preventing further postmenopausal bone loss[139,[17, 167, 168].  Some nutrition-related examples 
of research conducted on ovariectomized rodents with successful results in improving or 
maintaining bone parameters are nano calcium products[168], soy protein [163], and dried plum[17, 
167]
. 
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Pharmacological Options for Osteoporosis Treatment 
Drugs for the prevention and treatment of osteoporosis are classified as anti-resorptive or 
anabolic depending on their effect on bone remodeling[169].  Anti-resorptive drugs act by 
inhibiting OC formation, OC activity or by inducing premature osteoclast cell death.  Anti-
resorptive drugs include SERMs, bisphosphonates (alendronate, risedronate, ibandronate, and 
zoledronic acid), an estrogen agonist/antagonist (raloxifene), and calcitonin.  Some resorption 
inhibitors, such as SERMs, PTH, some interleukins, and Denosumab, inhibit OC formation by 
working on OBs since OBs secrete essential factors for OC differentiation such as M-CSF and 
RANKL [170].  Denosumab is a fully human monoclonal antibody (IgG2 immunoglobulin 
isotype) antiresorptive drug that has recently been approved for use in the US.  It functions by 
binding to RANKL, preventing it’s binding to RANK.  This results in a reduction in OC 
formation, activity and survival, thereby reducing the bone resorption rate [171]. Denosumab also 
has the advantage of being a subcutaneous medication administered every six months thereby 
improving long-term adherence to therapy compared with oral treatment options.  Calcitonin and 
aminobisphosphonates, on the other hand, work by inhibiting OC resorption activity, where as 
the first generation bisphosphonate, clodronate, works by inducing osteoclast apoptosis  [170] .   
Anabolic agents work by increasing osteoblast activity.  The only pharmaceutical 
anabolic agents to bone are teriparatide, a recombinant PTH, and strontium ranelate [172].  
Strontium ranelate has both antiresorptive and anabolic properties [173].  The present study looks 
at mango as a possible anabolic agent to bone, thereby reversing the effects of ovariectomy 
induced bone loss.   
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Nutrient Composition of Mango 
 
Mangos (Mangifera indica L) are excellent sources of vitamin C and vitamin A and are 
good sources of dietary fiber, potassium, copper, and vitamin K [28].  Mangos also contain 
minerals involved in bone health such as magnesium, zinc, copper, manganese, and selenium [29].  
Table 1 details the nutrient composition and daily value of the mango fruit.    
Table 1:  Nutrient composition of mango and percent daily values (DV).ab[28] 
aAmount of nutrient a food provides based on DRI (dietary reference intake) guide and reference 
values for nutrition labeling (2000 calories per day).  
b Values were obtained from USDA National Nutrient Database for Standard Reference, Release 
22 (2009) 
c
 Foods that provide %DV of ≥10% are considered a 'good' source; those ≥20% are considered 
an 'excellent' source.
Nutrient DV 
reference 
(units/day) 
Amount in 
100g mango 
% DVc Amount in 1 fruit 
(no peel or pit) 
         (207 g) 
% DVc 
Macronutrient 
Carbohydrate, g 300 17 5.7 35.2 11.7 
Protein, g 50 0.51 1.0 1.06 2.1 
Total fat, g 65 0.27 0.4 0.56 0.9 
Dietary fiber 25 1.8 7.2 3.7 14.8 
Minerals 
Calcium, mg 1000 10 1.0 21 2.1 
Potassium, mg 3500 156 4.4 323 9.2 
Phosphorus, mg 1000 11 1.1 23 2.3 
Copper, mg 2 0.110 5.5 .228 11.4 
Sodium, mg 2400 2 0.1 4 0.2 
Vitamins 
Vitamin A, IU 5000 765 15.3 1584 31.7 
Vitamin C, mg 60 27.7 46.2 57.3 95.5 
Vitamin K, ug 80 4.2 5.2 8.7 10.9 
Thiamin, mg 1.5 0.058 3.9 0.12 8.0 
Riboflavin, mg 1.7 0.057 3.4 0.118 6.9 
Folate, ug 400 14 3.5 29 7.2 
Vitamin E, IU 30 1.12 3.7 2.32 7.7 
Niacin, mg 20 0.584 2.9 1.209 6.0 
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Mangos also contain carotenoids, triterpenes, and phenolic compounds such as tannins, 
mangiferin and flavonoids which contribute to its antioxidant and anti-inflammatory functions.  
Total phenolics in mango vary depending on the cultivar and the processing methods.  Total 
phenolics of dry weight with peel ranges from 350 to 4860 mg/kg, while 60 to 180 mg/kg is 
common in the fresh fruit [174-177].  Mercadante and colleagues show the following carotenoid 
profile as detected  by HPLC and confirmed by mass spectrometry on a Brazilian mango 
cultivar, Keitt; β-carotene (all-trans), β-cryptoxanthin (all-trans and cis), zeaxanthin (all-trans), 
luteoxanthin isomers, violaxanthin (all-trans and cis), and  neoxanthin (all-trans and cis) [178].  
Carotenoid composition of the mango cultivar Keitt is shown in Table 2.  β –Carotene is a 
predominant carotenoid in mango and functions as pro-vitamin A.  Table 3 details the β –
Carotene and vitamin A content of various varieties of mango in their fresh and dried forms. 
Although the ripe mango flesh is not particularly high in flavonoids, higher amounts of 
flavonoids can be obtained by consuming them unripened and with the peel intact, a common 
practice done in Indian cuisine know as the spicy mango pickle (Table 4). 
Table 2:  Carotenoid Composition of Mango Cultivar Keitt Bahia, Brazil [178] 
 
carotenoid (µg/g)  range     meana 
all-trans-β-carotene   13.4-16.2    15.1 ± 1.5 
unidentified compound      0.2  ± 0.0 
cis- β -cryptoxanthin   tr-0.1     0.1  ± 0.1 
all-trans- β -cryptoxanthin  0.3-0.3    0.3  ± 0.0 
all-trans-zeaxanthin   0.6-0.9    0.8  ± 0.2 
luteoxanthin isomers   3.1-4.1    3.8  ± 0.6 
all-trans-violaxanthin   18.2-23.9    21.1 ± 2.9 
9-cis-violaxanthinb   9.9-10.3    10.1 ± 0.2 
13-cis-violaxanthinb   1.3-1.5    1.4 ± 0.1 
cis-neoxanthin   tr-0.2     0.1  ± 0.1 
all-trans-neoxanthin   1.0-3.6    2.1 ± 1.3 
total     49.9-59.8    55.0 ± 5.0 
vitamin A value   222-270    251 ± 26 
a
 Mean and standard deviation of three sample lots. b Tentative identification. 
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Table 3:  β -Carotene Content of Fresh and Dried Mango Flesh of Different Cultivars 
Samples all-trans- 9-cis-  13-cis-  relative amount    Vitamin A  
 β –carotene β –carotene β –carotene of cis-isomersa  valueb 
…  µg/100 g DWc µg/100 g DW µg/100 g DW  %                RE/100 g  
Kent 
fresh   4580   trd   1120    24.4   142 
driede   4270   180   1390    36.8   752 
Tommy Atkins 
fresh   3650   ndf   940    25.8   114 
driede   2510   trd   930    37.1   431 
Namdok Mai 
fresh   3650   trd   990    27.1   121 
solar-driedg  2400   810   730    64.2   425 
Kaew 
fresh   11,680  1010   1220    19.1   423 
solar-driedg  6820   2050   1430    51.0   1011 
a
 Calculated as percentage of all-trans-β-carotene.  
b
 Retinol equivalent (RE) according to Zechmeister (41).  
c
 Dry weight.  
d
 In traces.  
e
 Standard drying process (σa = 75 °C, aw = 0.6, tD  = 3-3.5 h).  
f Not detected.  
g Solar-drying process (aw = 0.6, tD = 7-8 h). 
 
Table 4:  Total phenolic and total flavonoid content of mango: flesh/ peel, ripe/unripe[179]  
Samples          Total phenolic content                       Total flavonoid content 
(mg GAE/g)     (mg RE/g) 
Unripe Mango Flesh    27.8 ± 2.21     8.15 ± 1.54 
Unripe Mango Peel    92.6 ± 3.40     22.2 ± 3.32 
Ripe Mango Flesh    26.9 ± 3.76     3.30 ± 0.79 
Ripe Mango Peel    70.1 ± 4.61     21.2 ± 2.47 
All data are presented as mean ± SD of the three replicates. GAE: gallic acid equivalents, RE: 
rutin equivalents.    
 
 
Studies on Health Benefits of Mango Pulp 
 
Different parts of the mango fruit and tree has been investigated for its health benefits. In 
addition to the mango pulp, the kernel, peel, leaves, stem and bark have all been utilized for 
research. Research on the different parts of mango fruit and tree have explored its antioxidant 
and anti-inflammatory properties, anti-bacterial, anti-viral, anti-HIV, anti-cancer, anti-diabetic, 
anti-atherogenic, and  immune-modulatory  properties as well as functions in bone health [180-183]. 
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The bulk of the research on mango has utilized the stem bark extract of mango that is rich in the 
phenolic compound mangiferin. Table 5 lists the pharmacological activity of mangiferin 
extracted from mango tree bark. Since our study has used mango pulp, this section will focus on 
research that has been done on mango pulp and some of the research done on mango related to 
bone. 
The pulp of the mango has been investigated as a chemo-protective agent via its 
antioxidant functions.  A study conducted by Percival et al. in 2005[184], showed that mango juice 
inhibits cancer cell growth.  Lupeol, a naturally occurring pentacyclic triterpene present in 
mango pulp and other fruits, was shown to exhibit strong anti-inflammatory, anti-arthritic, anti-
mutagenic and anti-malarial activity [185]. The effects of lupeol/mango pulp extract in 
testosterone induced oxidative stress in the prostate of male Swiss albino mice were also 
examined [185].  Lupeol/ mango pulp extract treated mice had lower ROS levels and restored 
levels of lipid peroxidation and antioxidant enzymes catalase, superoxide dismutase, glutathione 
reductase, and glutathione-S-transferase.  In this study, lupeol/mango pulp extract was effective 
in combating oxidative stress-induced cellular injury of mouse prostate, indicating a protective 
role in prostate cancer [185].  The anti-tumor effects of lupeol have also been demonstrated in 
mouse skin in a study done by Saleem et al. (2004)[186, 187].  The antioxidant properties of lupeol 
have also demonstrated a hepatoprotective effect using cadmium-induced hepatotoxic rats [188].  
Hepatoprotective effects of lupeol and mango pulp extract were also demonstrated in a 
carcinogen induced (dimethylolbutanoic acid) mouse model [189].  The endogenous antioxidant 
enzyme status was restored and a decrease in lipid peroxidation was observed.  
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Mango and Bone Health 
We are only aware of a few studies investigating the effect of mango on bone. Er- Xian 
Decoction, has long been used for the treatment of osteoporosis and menopausal syndrome in 
China. Bioactivity-guided fractionation of Er Xian decoction has led to the successful isolation 
of the anti-osteoporotic constituents, identifying one as mangiferin [190].  
Another study investigated the effect of the xanthonoid compound found in mangoes, 
mangiferin, on periodontitis [191].  Periodontitis is a chronic inflammatory disease related to the 
formation of colonies of microorganisms present in subgingival plaque leading to inflammatory 
periodontal pockets, destruction of the periodontal ligaments, alveolar bone resorption and tooth 
loss[192]. Carvalho and colleagues (2008)[191], induced periodontitis in Wistar  rats by applying a 
ligature around the lower right first molar with subsequent oral treatment of  100 mg/kg 
mangiferin for 1, 4 or 7  days.  Oral administration of mangiferin significantly reduced alveolar 
bone loss and cellularity, inhibited COX-2 expression and the adhesion of leukocytes, while 
maintaining normal lipoxin A4 levels. Lipoxin A4 acts as an endogenous anti-inflammatory 
mediator by its anti-chemotaxic action in inhibiting the rolling of leukocytes. The mangiferin-
treated rats presented an earlier peak of cell proliferation and augmented angiogenesis in the 
injured region.   
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Table 5:  Pharmacological activity studies on mangiferin from mango bark [193]
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CHAPTER III 
 
 
METHODOLOGY 
This study was designed to determine the dose-dependent effects of freeze-dried mango 
pulp on reversing ovariectomy-induced bone loss.  To mimic a post-menopausal state, the 
ovariectomized mice model was used.    
 
Animal Grouping  
Thirty 12–week old ovariectomized (OVX) mice and 14 sham-operated (SHAM) 
C57BL/6 mice were purchased from Charles River Laboratory (Kingston, NY) and housed in 
Oklahoma State University (OSU) animal research laboratory.  Mice were fed a standardized 
AIN-93M powdered rodent diet [194] for two weeks post-ovariectomy.  All animal handling and 
procedures were approved by Institutional Animal Care and Use Committee at OSU.  
After a 2 week period, a total of 12 mice (n= 6 SHAM; n= 6 OVX) were necropsied to 
confirm ovariectomy-induced bone loss.  Whole body dual-energy X-ray absorptiometry (DXA) 
scans were preformed prior to necropsy.  The remaining 32 mice were weighed and divided into 
4 groups and housed in groups of four mice per cage.  Mice were assigned to one of the 
following dietary treatment groups (n = 8 mice/ group) for 8 weeks:  (1) SHAM - control diet; 
(2) OVX - control diet; (3) OVX - 5% dried mango diet; and (4) OVX - 25% dried mango diet.    
The OVX groups were match-fed to the SHAM group.  All mice were provided deionized water 
ad libitum and were weighed weekly.
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Diet Formulation 
Ripe Tommy Atkins variety mangoes were purchased from a local grocery store.  The 
pulp was separated from the skin and kernel and freeze-dried.  The freeze-dried mango pulp was 
ground to a powder and sent to Nestle Purina Analytical Laboratories (St. Louis, MO) for 
analysis of macronutrients and calcium and phosphorous content (Table 6).  Freeze-dried mango 
powder was incorporated into the diet at 5% or 25% concentration by weight.  The macro-
nutrient composition as well as the calcium and phosphorus content of the mango diets were 
adjusted to be similar to the control diet (Table 7).  The control diet was an AIN-93M 
formulation containing 72% carbohydrate, 4% fat and 14% protein by weight [194].   
Table 6: Macronutrient, calcium and phosphorus content of freeze dried mango powder 
(TommyAtkins variety) used in the study. * 
Parameter Amount (g/100g) 
Carbohydrate 73.70 
Protein 4.80 
Fat 2.89 
Crude Fiber 7.58 
Ash 3.00 
Calcium 0.0854 
Phosphorus 0.115 
Calories 340 
*Analysis performed by Nestle Purina Analytical Laboratories (St. Louis, MO) 
 
Necropsy, Tissue Processing, and Storage 
After eight weeks of dietary treatment, mice were fasted for 12 hours, weighed and 
injected with ketamine/xylazine cocktail (80 and 8 mg/kg body weight, respectively). Body 
composition was determined using DXA (GE Lunar Piximus, Fitchburg, WI). Blood was 
collected via exsanguination from carotid artery and placed into ethylenediamine-tetraacetic acid 
(EDTA) coated tubes. Plasma was obtained by centrifugation of whole blood for 20 minutes at 
1300 X g and stored at -80°C for later analyses. Thymus, spleen, liver and uterus were removed  
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Table 7:  Diet composition 
 Control 
(AIN-93M)* 
5% Mango 25% Mango 
Ingredients (g/kg)    
Dried mangoa  50.0 250 
    
Total Carbohydrate 720.7 720.7 720.7 
     Cornstarchb 465.7 428.9 281.5 
     Maltodextrinb 155.0 155.0 155.0 
     Sucroseb 101.1 101.4 102.4 
     Dried mangoa  36.6 184.3 
      
   
Total Protein 140.0 140.0 140.0 
     Caseinb 140.0 137.6 128.0 
     Dried mangoa  2.4 12.0 
      
   
Total Fat 40.0 40.0 40.0 
     Soybean oilb 40.0 38.6 32.8 
     Dried mangoa  1.5 7.2 
      
   
Total Fiber 50.0 50.0 50.0 
     Celluloseb 50.0 46.2 31.1 
      Dried mangoa  3.8 18.9 
 
   
Vitamin Mixb 10.0 10.0 10.0 
 Total Mineral Mix 35.00 35.00 35.00 
     Mineral Mixb  
     (Ca & P deficient) 
13.40 13.40 13.40 
     Calcium carbonateb 12.50 12.39 11.97 
     Calcium from mangoa  0.04 0.21 
     Sodium phosphatec                
monobasic (NaH2PO4) 
5.60 5.48 5.03 
     Potassium phosphated   
monobasic (KH2PO4) 
2.40 2.36 2.16 
     Phosphorus from 
mangoa 
 0.06 0.29 
 
   
Choline bitartrateb 2.50 2.50 2.50 
L-cysteinb 1.80 1.80 1.80 
*Based on AIN-93M formulations containing 72% carbohydrate, 4% fat and 14% protein by 
calories (Reeves et al., 1997). 
a Freeze dried Tommy Atkins Mango Pulp 
bHarlan Teklad Diets (Madison, WI) 
cSigma Aldrich Co. (St. Louis, MO) 
dFisher Scientific Bio Reagents (Fair Lawn, NJ) 
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and weighed.  A portion of abdominal white adipose tissue was collected and stored in formalin 
with the remainder snap-frozen in liquid nitrogen and stored at -80°C.   
The femurs, tibiae, and spine were removed.  Femurs and tibiae were cleaned of 
surrounding soft tissue.  The tibiae were stored in 70% ethanol and the femurs snap frozen in 
liquid nitrogen and stored at -80°C.  Spines were collected and stored at -20°C.   
 
Body Composition and Bone Mineral Density (BMD) Assessment 
Whole body, tibial, and vertebral bone mineral density (BMD), bone mineral content 
(BMC), bone mineral area (BMA) as well as total body composition (i.e. lean and fat mass, and 
% body fat) were assessed using DXA (Lunar PIXI, GE Medical Systems, Madison, WI) with 
PIXImus Series Software version 1.4X.  Percent fat free mass was calculated using total body 
composition and lean tissue weight.  A quality control phantom mouse was scanned before 
sample measurements were taken to assure no more than 2% error in measurements.  Mice were 
spread with the frontal/coronal plane down, limbs extended away from the body, and the tail was 
not included in the scan. A region of interest (ROI) was selected after the scan was taken with 
the head excluded from analysis as recommended by the manufacturer.   
 
Bone Micro-Architecture Assessment  
Micro-architecture trabecular parameters of the spine were assessed using micro-
computed tomography (Scanco µCT 40 scanner; SCANCO Medical, Switzerland).  Scans were 
taken using 2048 x 2048 pixels.  The area between L4 and L5 lumbar vertebrae was analyzed by 
acquiring 160 ± 5 slices (600 µm) and evaluating in the volume of interest (VOI).  Semi-
automated contours were placed starting 10 slices (60 µm) distal to the growth plate to assess 
secondary spongiosa within the VOI.  Trabecular bone volume expressed per unit of total 
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volume (BV/TV), trabecular number (TbN), trabecular separation (TbSp), and trabecular 
thickness (TbTh), were determined and connectivity density (ConnDens) and structural model 
index (SMI) were calculated. The bone volume fraction is a measure of the volume of bone 
tissue (including internal pores like lacunae and canaliculi) per total volume.  
 
Bone Strength Assessment  
Bone strength was assessed using finite element (FE) pressure simulation on the µCT 
images of the area between L4 and L5vertebra (SCANCO Medical). The FE data is obtained by 
converting bone voxels, which represent the bone tissue, from the VOI into 8-node brick 
elements using a meshing technique [194].  FE uses compression on the simulated reconstructed 3-
D images of the spine to determine the total force and size-independent stiffness [195].   
 
Biomarkers of Bone Homeostasis 
The bone formation marker, N-terminal propeptide of procollagen type 1 (PINP), and 
bone resorption marker, pyridinoline (PYD), were assessed in the plasma.  Both biomarkers were 
assessed using enzyme-immuno-assays (EIA).  PINP was purchased from Immunodiagnostic 
Systems Ltd. (Fountain Hills, AZ) and PYD from Quidel Corporation (San Diego, CA).  The 
PINP assay used a polyclonal rabbit anti-PINP antibody.  Standards, controls, and samples were 
added to a 96-well plate in duplicate.  PINP labelled with biotin was then added and incubated 
for 1 hour at room temperature. Well contents were then decanted and the wells were washed 
three times with wash solution.  Enzyme conjugate (PBS with avidin linked to horseradish 
peroxidase) was then added to all wells and incubated for another 30 min.  Wells were again 
washed three times and tetramethylbenzidine substrate was added to all wells and incubated for 
30 min.  The reaction was stopped with hydrochloric acid and absorbance was measured at 450 
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nm using a microplate reader.  A standard curve was created using the mean of each standard for 
the ordinate and the PINP concentration (abscissa) and was in read in ng/mL.  PINP 
concentration values were multiplied by the dilution factor used (x10)   
In the PYD assay (MicroVueTM), PYD in the samples or standards competes with the 
PYD on the micro plate for polyclonal rabbit anti-PYD antibody.  The bound antibody is then 
detected by goat anti-rabbit antibody conjugated to alkaline phosphatase.  This reaction is 
detected with pNPP substrate.  The plasma sample was filtered through 30k MWCO Spinfilter 
by centrifugation for 30 min at 3,000xg-10,00xg to obtain the sample filtrate used in the assay.  
Diluted standard, control or undiluted filtered plasma sample was then added to each well of the 
coated strip followed by the addition of PYD antibody.  The plate was covered with an adhesive 
plate sealer and incubated overnight in the dark at 2-8ºC.  Wells were decanted, washed with 
wash buffer, and enzyme conjugate was then added to each well followed by incubation for one 
hour.  Wells were washed again with wash buffer followed by addition of working substrate 
solution and incubation for 40 minutes at room temperature.  The reaction was stopped by the 
addition of sodium hydroxide stop solution and absorbance was read at 405 nm using a 
microplate reader.  The results were analyzed with a 4 parameter calibration curve.   
 
Statistical Analyses 
Statistical analyses used a student’s t - test and were derived using least square means and 
standard deviation (SD) for each treatment group using SAS version 9.1 (SAS Institute, Cary, 
NC).  Analysis of variance and least square means were computed using the general linear model 
procedure and the means were compared using Fisher’s least significant difference for 
comparing groups. Differences were considered significant at P values < 0.05.
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CHAPTER IV 
 
 
            FINDINGS 
 
 
Baseline Data 
 
Two weeks post-ovariectomy, a baseline group of SHAM (n = 6) and OVX (n = 6) mice 
were necropsied to confirm bone loss prior to dietary treatment.  A significant decrease in whole 
body BMD was observed in the OVX mice when compared to that of that of the SHAM mice 
(Table 8).  However, no significant differences were observed in the BMD of the tibia or in the 
lumbar vertebrae (L4 and L5).  In addition, there were no significant differences in both BMC 
and BMA of the whole body, tibia or vertebrae at two weeks post-ovariectomy between OVX 
and SHAM-operated mice. There were also no significant differences in plasma concentrations 
of the bone formation marker, N-terminal propeptide for type I procollagen (PINP), or the bone 
resorption marker, pyridinoline (PYD), in the ovariectomized and SHAM-operated C57/BL6 
mice prior to dietary treatment. 
Being that the ovaries were removed from the OVX group, the uterine tissue weights of 
the SHAM mice were higher than that of the OVX mice (Table 8) indicating success of the 
ovariectomy procedure.  No significant differences in liver, spleen, and thymus weights were 
observed between the SHAM and OVX mice.  Body composition also did not vary between the 
SHAM-operated and OVX groups after two weeks of surgery. However, fat mass tended 
(P=0.0516) to be lower in the OVX mice compared to the SHAM mice.  
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Effects of dried mango on weekly body weights of ovariectomized mice 
Before the dietary treatment initiation, mice had similar body weights.  After the first 
week of feeding, significant changes in body weight were already observed between the SHAM 
and OVX mice (Table 9). All OVX mice experienced similar weight gain during the first four 
weeks of dietary treatment (Table 9).  However, during the last four weeks of treatment, the 
OVX mice receiving the control diet weighed more than the ones receiving the mango diet, 
despite similar food intake (Table 9).  Among the OVX group mice, the 25% mango diet group 
had lower body weights than the OVX control and 5% mango group, although still higher than 
the SHAM animals.  At the time of necropsy, 25% mango group mice had weights that were 
statistically similar to the SHAM animals.  The 5% mango group had body weights that were 
similar to the 25% mango as well as to the OVX control group.   
 
Effects of dried mango on food intake, tissue weights, whole body bone parameters and 
body composition of ovariectomized mice 
Throughout the duration of the study, OVX mice were matched-fed to the SHAM mice.  
The average food intake throughout the duration of the study for ovariectomized mice was less 
than the SHAM mice.  The OVX mice were matched-fed the food intake of the SHAM group 
that is one feeding cycle behind.  Despite lower food intake by OVX mice when compared to 
SHAM mice, the weekly body weights of OVX mice were higher than those of the SHAM mice 
(Table 9). 
Spleen, thymus and liver weights were not significantly different among treatment 
groups.  Similar to baseline measurements, uterine weights of SHAM mice were significantly 
higher than OVX mice (Table 10). 
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The addition of mango to the diet modulated body composition, similar to the effects 
observed on body weight (Table 10).  Fat mass and % body fat were highest in the OVX control 
mice.  Both doses of mango reduced fat mass and % body fat but not to the level observed in the 
SHAM animals.  Lean mass was not significantly different among treatment groups, but was 
different when expressed as a percentage of total mass (% fat-free mass).  SHAM mice had the 
highest percentage of fat-free mass, followed by both mango-fed groups.  The OVX control mice 
had the lowest % fat-free mass. 
 
Effects of dried mango on bone parameters: whole body, tibia, and lumbar vertebrae (L4 
and L5)  
After 8 weeks of dietary treatment, mice in the OVX group lost more bone when 
compared to SHAM animals.  OVX group mice had significantly lower whole body, tibia, and 
lumbar BMD and BMC when compared to the SHAM control mice (Table 11).  Whole body, 
tibial and lumbar BMD of the mice given both mango diets were not different from the OVX 
mice which received the control diet.  
 Similarly, whole body and vertebral BMC were not affected by the addition of mango to 
the diet.  Both the mango groups had whole body and vertebral BMC that were not statistically 
different from the OVX control group mice.  In contrast, tibial BMC was increased by both doses 
of mango, with 5% mango diet increasing it to levels similar to SHAM mice (Table 11).   
Whole body BMA was similar for all the OVX mice and significantly lower compared to 
the SHAM animals. Lumbar BMA of OVX control mice and 25% mango group mice were 
similar to that of the SHAM control mice.  Mice receiving the 5% mango dose had the lowest 
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BMA. The opposite effect was observed with tibial BMA.  The mice receiving the mango diets 
had higher BMA compared to those receiving the control diet (Table 11).   
As expected, OVX animals had inferior microarchitectural parameters of the vertebra 
compared to the SHAM mice regardless of dietary treatment (Table 12).  OVX mice had lower 
vertebral BV/TV, Conn. D., TbN, TbTH, Mean TV and Mean BV than SHAM animals.  
Supplementation of mango, at either dose, was not able to restore the deterioration of the micro-
architectural parameters resulting from the ovariectomy.   
Finite element analyses demonstrate that ovariectomized mice had lower size 
independent stiffness and total force in comparison to the SHAM mice (Table 12).  Dietary 
treatment had no significant effects on vertebral strength of OVX mice 
Effects of dried mango on plasma markers of bone formation and resorption 
 
N-terminal propeptide for type I procollagen (PINP), a serum marker of bone formation, 
was not significantly different between any of the groups but tended (P = 0.0510) to be lower in 
the mango groups (Table 13).  Plasma pyridinoline (PYD), a marker of bone resorption, was 
significantly higher in OVX when compared to SHAM mice.  PYD values are inversely 
proportional to the level of bone resorption.  Bone resorption rates were similar between all OVX 
groups.  Mango was not able to attenuate changes in bone resorption markers due to 
ovariectomy.
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Table 8: Baseline characteristics of ovariectomized (OVX) and SHAM-operated C57/BL6 mice 
two weeks post-ovariectomy (prior to dietary treatment).  
Sham  OVX  P  Value 
Bone Parameters 
Whole Body 
     BMD (mg/cm2) 49.8 ± 1.1  48.0 ± 1.3  0.0269 
     BMC (mg) 539.5 ± 33.6  539.5 ± 32.7  1.0000 
     BMA (cm2) 10.83 ± .456  11.24 ± .530  0.1798 
 
   
Tibia 
     BMD (mg/cm2) 44.48 ± 2.26 45.30 ± 2.41 0.5586 
     BMC (mg) 19.00  ± 0.89 18.83 ±   1.17 0.7872 
     BMA (cm2) 0.43 ± 0.02 0.42 ± 0.01 0.4160 
 
   
Lumbar Vertebrae (L4 and L5) 
     BMD (mg/cm2) 49.85 ± 3.23 50.32 ± 4.2 0.8337 
     BMC (mg) 114.0 ± 21.16 118.83 ± 10.07 0.6243 
     BMA (cm2) 2.28 ± 0.35 2.36 ± 0.10 0.5921 
Tissue Weights 
Uterus (mg) 133.3 ± 52.8 33.3 ± 5.2 0.0010 
Liver (mg) 803.3 ± 43.2 916.7  ± 154.9 0.1150 
Spleen (mg) 76.7 ± 10.3 81.7 ± 35.4 0.7470 
Thymus (mg) 51.7 ± 9.8 60.0 ± 16.7 0.3177 
Body composition  
Lean mass (g) 14.0 ± 0.51  13.71 ± 0.78 0.4739 
Fat mass (g) 4.07  ± 0.16  3.85 ± 0.18 0.0516 
Total mass (g) 18.05 ± 0.50  18.22 ± 2.13  0.8559 
% Fat  22.45 ± 1.08  21.83 ± 0.68 0.2630 
% Fat-free mass 77.54 ± 1.09 76.15 ± 5.01 0.5190 
Plasma 
PINP (ng/ml) 35.39 ± 6.64 32.94 ± 7.27 0.5564 
PYD (ng/ml) 1.92 ± 0.65 2.49 ± 0.97 0.2649 
Values are mean ± SD (n=6/group), P < 0.05 were considered significant. BMD, bone mineral 
density; BMC, bone mineral content; BMA, bone mineral area.   
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Table 9:  Effect of freeze -dried mango supplementation on weekly body weights of 
ovariectomized (OVX) mice 
 Control 
SHAM 
 (g) 
Control 
OVX 
(g) 
5% Mango 
OVX  
(g) 
25%  
Mango OVX 
(g) 
P value 
Baseline 19.7  ± 1.0 20.4 ± 1.0 20.6 ± 0.9 20.5 ± 0.8 0.2477 
Week 1 18.7 ± 0.7b 20.1 ± 1.1a 20.2 ± 1.2a 20.6 ±0.9a 0.0047 
Week 2 20.6 ± 1.1b 22.4 ± 1.1a 22.3 ± 0.8a 22.6 ± 1.0a 0.0014 
Week 3 20.8 ± 1.4b 23.3 ± 1.4a 23.0 ± 1.3a 23.4 ± 1.6a 0.0025 
Week 4 21.7 ± 1.1b 25.0 ± 1.2a 24.3 ± 1.8a 23.8 ± 1.6a 0.0006 
Week 5 22.4 ± 0.5c 27.1 ± 1.4a 24.9 ± 1.8b 24.5 ± 1.6b <.0001 
Week 6 23.0 ± 1.1c 29.1 ± 1.6a 26.3 ± 2.3b 25.7 ± 2.3b <.0001 
Week 7 23.8 ± 1.8c 30.3 ± 2.0a 28.0 ± 2.7ab 26.4 ± 2.4b <.0001 
Week 8 24.0 ± 2.0c 30.9 ± 1.9a 28.5 ± 3.3ab 27.3 ± 2.5b <.0001 
Final 24.9 ± 1.7c 31.2 ± 2.0a 28.8 ± 4.2ab 28.2 ± 3.0bc 0.0019 
 
Values are mean ± SD, n=8/group; within a row, values that do not share the same letters are 
significantly different (P<0.05) from each other.
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Table 10:  Effects of freeze-dried mango supplementation on food intake, tissue weights, and 
body composition of ovariectomized (OVX) mice 
 Control 
SHAM 
Control 
OVX 
5% Mango 
OVX 
25% Mango 
OVX 
P Value 
Food intake (g) 4.8 ± 1.1a 3.6 ± 1.0b 3.8  ± 0.8b 3.8  ± 0.9b <.0001 
 
Tissue Weights (mg) 
Uterus  102.5 ±  29.2a 23.1 ± 12.8b 18.6 ± 12.1b 17.5 ± 7.1 b <.0001 
Spleen 92.5 ± 15.8 100.0 ± 9.3 106.2 ± 32.0 98.8 ± 14.6 0.5923 
Thymus  70.0 ± 24.5 82.5 ± 17.5 85.0  ± 18.5 86.2 ± 14.1 0.3178 
Liver  986.7 ± 119.1 1143.3 ± 162.1 991.4 ± 162.8 1091.4 ± 
117.5 
0.1672 
 
Body Composition 
Lean mass (g) 17.29 ± 1.0 18.72 ± 0.6 18.16  ± 1.5 18.25 ± 1.4 0.1288 
Fat mass (g) 6.19 ± 0.9c 11.68 ± 1.7a 9.58  ± 2.8b 8.66 ± 2.1b <.0001 
Total mass (g) 23.50 ± 1.8c 30.41 ± 2.3a 27.74 ± 4.1ab 26.90 ± 3.4b 0.0011 
% Fat  26.2 ± 1.8c 38.3 ± 2.7a 33.8 ± 5.3b 31.7 ± 4.4b <.0001 
% Fat free mass 73.7 ± 1.8a 61.7 ± 2.7c 66.1 ± 5.2b 68.3 ± 4.3b <.0001 
Values are mean ± SD, n=8/group; within a row, values that do not share the same letters are significantly 
(P < 0.05) different from each other.  
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Table 11:  Effects of freeze-dried mango supplementation on whole body, tibia and lumbar 
vertebrae (L4 and L5) bone mineral density (BMD), content (BMC), and area (BMA) of 
ovariectomized (OVX) mice 
 Control 
SHAM 
Control 
OVX 
5% Mango 
OVX 
25% Mango 
OVX 
P Value 
Whole Body  
BMD (mg/cm2) 53.8 ±  1.5a 47.3 ± 1.0 b 48.0 ± 1.6 b 48.3 ± 1.3 b <.0001 
BMC (mg) 564.1 ± 43.0a 414.9 ± 40.0 b 444.9  ± 54.8b 450.4 ± 16.7 b <.0001 
Area (cm2) 10.5 ±  0.6a 8.8 ± 0.7 b 9.2 ± 0.9 b 9.33 ± 0.4 b 0.0002 
      
Tibia 
BMD (mg/cm2) 49.79 ± 1.02a 43.65 ± 1.76b 42.58 ± 1.33b 43.36 ± 0.86b <.0001 
BMC (mg) 18.75 ± 1.16a 16.00 ± 1.51c 17.75 ± 1.58ab 17.38 ± 0.92b 0.0029 
BMA (cm2) 0.38 ± 0.02b 0.37  ± 0.02b 0.42 ± 0.03a 0.40 ± 0.02a 0.0006 
      
Lumbar Vertebrae (L4 and L5) 
BMD (mg/cm2) 56.66 ± 4.7a 44.13 ± 2.7b 45.51 ± 3.9b 45.61 ± 2.7b <.0001 
BMC (mg) 17.00 ± 1.7a 13.00 ± 1.5b 12.25 ± 1.4b 13.00 ± 1.2b <.0001 
BMA (cm2) 0.30 ± 0.02a 0.30 ± 0.02a 0.27 ± 0.02b 0.29 ± 0.02ab 0.0049 
Values are mean ± SD, n=8/group; within a row, values that do not share the same letters are 
significantly different (P < 0.05) from each other.
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Table 12:  Effects of freeze-dried mango supplementation on microarchitectural parameters and 
strength of lumbar vertebra (L4 and L5) of ovariectomized (OVX) mice 
 SHAM Control 
OVX 
5% Mango 
OVX 
25% Mango 
OVX 
P Value 
Microarchitectural parameters  
 
BV/TV (%) 19.1 ± 1.0a 11.4 ± 1.4b 10.3 ± 0.6b 11.4 ± 1.4b <.0001 
Conn. D. (1/mm3) 120.0 ± 17.0a 85.0 ± 18.2b 73.9 ± 9.8b 86.3 ± 13.7b 0.0002 
SMI (1) 1.24 ± 0.14b 1.82 ± 0.12a 1.97 ± 0.11a 1.84 ± 0.15a <.0001 
TbN (1/mm) 3.64 ± 0.13a 3.24 ± 0.25b 2.94 ± 0.37b 3.14 ± 0.23b 0.0012 
TbTH (µm) 56.20 ± 1.13a 45.98 ± 2.02b 45.55 ± 1.71b 46.07 ± 1.68b <.0001 
TbSp (µm) 275.37 ± 
11.11c 
312.87 ± 26.50b 348.07 ± 
42.82a 
322.17 ± 
23.65ab 
0.0025 
Mean TV 
(mg HA/µm) 
292.94 ± 
12.80a 
206.98 ± 26.88b 194.37 ± 
30.13b 
218.48 ± 
15.97b 
<.0001 
      
Mean BV 
(mg HA/µm) 
1082.99 ± 
20.19a 
1064.85 ± 6.74ab 1057.03 ± 
15.25b 
1048.28 ± 
31.32b 
0.0479 
 
Bone strength by finite element analysis 
Von Mises  
(MPa x 10-3) 
1457.1 ± 
400.3 
1216.2 ± 
162.7 
1268.0 ± 
263.5 
1252.9 ± 
238.8 
0.4674 
      
Total Force  
(N x 10-3) 
218.3 ± 
82.4a 
103.6 ± 
34.9b 
102.8 ± 
29.9b 
103.8 ± 
32.8b 
0.0016 
      
Size Independent 
Stiffness (N/m) 
20914.2 ± 
6222.1a 
9491.8 ± 
2943.4b 
8894.2 ± 
2468.5b 
9524.6 ± 
2995.6b 
0.0001 
Values are mean ± SD, n=6/group; within a row, values that do not share the same letters are 
significantly different (P < 0.05) from each other. BV/TV - bone volume fraction; Conn. D. -
connectivity density; SMI - structure model index; TbN - trabecular number; TbTH - trabecular 
thickness;  TbSp - trabecular separation; Mean TV - mean total volume; Mean BV - mean bone 
volume.
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Table 13:  Effects of freeze-dried mango supplementation on marker of bone formation, PINP, 
and bone resorption, PYD, of ovariectomized (OVX) mice 
 Control 
SHAM 
Control 
OVX 
5%Mango 
OVX  
Mango 25% 
OVX 
P Value 
PINP 
(ng/mL) 
27.33  ± 11.26 25.92 ± 6.03 19.56 ± 7.09 18.34  ± 2.72 0.0510 
PYD 
(ng/mL) 
2.97  ± 0.77a 1.70 ± 0.37b 1.49 ± 0.41 b 1.47  ± 0.22 b <0.0001 
Values are mean ± SD, n=8/group; within a row, values that do not share the same letters are 
significantly different (P < 0.05) from each other. PINP, N-terminal propeptide for type I 
procollagen; PYD, pyridinoline.
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CHAPTER V 
 
 
CONCLUSION 
 The purpose of this study was to determine whether freeze-dried mango pulp powder 
supplementation, in 5 and 25% doses, could reverse bone loss in ovariectomized mice.  The null 
hypothesis was accepted in that mango was not able to restore the ovariectomy induced bone loss 
as evidenced by whole body, vertebral, and tibial BMD measurements, micro-architectural 
parameters and biomechanical properties of the lumbar vertebrae, and had no effect on serum 
markers of bone formation (PINP) or bone resorption (PYD).  Although mango was not effective 
in reversing ovariectomy- induced bone loss, it did modulate body weight and % body fat.   
Although mango has no effect on BMD, some positive effects were observed on BMC.  
Whole body and lumbar BMC did not differ from the OVX control diet, but BMC of the tibia 
was improved with mango supplementation.  The 5% dosage even restored tibial BMC to SHAM 
levels.  However, when looking at BMC it is important to consider it in relation to BMA.  The 
higher tibial BMA in the mango groups explains why the BMC is also higher.  Although the tibia 
may not be the best place to detect ovariectomy induced bone loss in mice, according to Lynch 
and colleagues (2010)[165], in human subjects, the tibia is a valuable assessment measurement for 
osteoporotic bone loss due to the fact that tibial cortical bone decreases about 5.6–11.0% every 
10 years in women while only an average of 5.5% is lost every 10 years at the femoral neck.
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Even though tibial BMC and BMA of the mango group are higher than controls, it has 
been pointed out that BMD accounts for 60-80% of the variations observed in bone strength [3, 
196]
.  It is also important to recognize that the relationship between BMD, BMC and BMA may 
be different at different bone sites.  For example, a study conducted on 1449 women over 30 
years of age by Deng and colleagues in 2002[197], demonstrated that, at the spine, 86.2% of BMD 
variation was attributable to BMC and 12.6% to bone area while at the hip, 98.0% of BMD 
variation was due to BMC and 1.1% due to bone area.  
As expected, micro-architectural parameters in the OVX mice were significantly lower 
than all SHAM mice as assessed by micro-computed tomography.  MicroCT delivers high 
resolution 3D images which directly measure bone micro-architecture with excellent 
reproducibility and accuracy [198].  X-ray snapshots at multiple viewing angles are reconstructed 
to a 3D image which shows the spatial distribution of the bone at the micrometer voxel size.  
Samples were contoured by hand every ten slices with algorithms used to complete the slices in 
between with the exclusion of cortical bone.  Mango did not exert an influence on the micro-
architectural parameters in the secondary spongiosia (trabecular bone) of the lumbar vertebra.  
Bone volume fraction (BV/TV), the ratio of segmented bone volume to the total volume of the 
region of interest, was not influenced by mango.  Connectivity density, trabecular number, 
thickness, mean total volume, and mean bone volume were also not affected by mango.  The 5% 
mango group mice did exhibit greater trabecular space which is associated with a weaker micro- 
architectural arrangement.  The structural model index estimates the plate verses rod 
characteristics of the trabecular bone [198].  Zero values represent plate arrangement while a value 
of 3 represents rods and 4 represents spheres.  All OVX mice exhibited higher SMI values than 
SHAM mice indicating more rod like arrangements than the SHAM animals.  Changes of 
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trabeculae from plate-like to rod-like are known to occur in aging, bone remodeling, and 
osteoporosis [199] indicating that the OVX mice were experiencing more bone remodeling than 
SHAM animals as evidenced by the SMI values. 
Bone strength was also not improved by mango supplementation.  Von Mises stress is 
calculated by combining stresses in three dimensions, with the result compared to the tensile 
strength of the material loaded in one dimension, yielding one numeric measurement[199]. Von 
Mises stress did not differ between OVX and SHAM animals.  This may be due to the fact that 
animal bones do not tend towards fracture and have a high resiliency to pressure despite their age 
or hormonal influences [200].  Biomechanical assessment measurements of total force and size 
independent stiffness, however, were lower in OVX mice indicating that with estrogen 
withdrawal there is a subsequent loss in bone strength.  Mango supplementation did not improve 
biomechanical properties of the bone when compared to the OVX control diet mice.  Using 
different evaluation tools may help to further evaluate the effect of mango on bone strength.  For 
example, quantitative ultrasound  measurements can also reflect bone elasticity, fragility and 
density closely associated with bone strength and fracture risk [201].   
 Although many biological compounds may assist in preventing bone loss, few agents are 
successful at reversing the bone loss associated with osteoporosis.  Fruits and vegetables or their 
bioactive compounds may be effective in alleviating the inflammatory environment associated 
with the postmenopausal unregulated production of pro-inflammatory cytokines and may also 
exert a protective antioxidant effect on the bone tissue while supplying important vitamins and 
minerals necessary for reversing bone loss.  Although the OC secretes ROS under normal bone 
remodeling conditions to assist with the destruction of calcified bone tissue, in a postmenopausal 
low estrogen state, the increased ROS production with the increase in bone resorption may 
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overwhelm the bodies endogenous antioxidant system and lead to osteoporosis [202, 203] .  
Sheweita and Khoshhal suggested that the enhanced OC activity may increase the superoxide 
anion generation and/or inhibit superoxide dismutase and glutathione peroxidase activities[112].  
Mango possesses antioxidants, such as the carotenoids, flavonoids, triterpenes, phenolic 
compounds and vitamin C, which, in theory, may help attenuate the inflammatory environment 
associated with osteoporosis.   
Some studies have demonstrated the effectiveness of bioactive food compounds in 
improving bone quality or preventing bone loss but few have shown bone loss reversal.  For 
example, citrus pulp, containing high amounts of flavonoids and vitamin C, improved BMD in 
male orchidectomized rats [14, 15].  Pholridzin in apples, rutin, and isoflavones have all prevented 
further bone loss in ovariectomized rats [20].  Green tea polyphenols reduced bone micro-
architecture deterioration in female rats [116] and blueberries prevented whole body BMD loss in 
OVX rats[167].  To our knowledge, only dried plum has been demonstrated to effectively restore 
bone that has been lost [17].  Dried plum polyphenols not only inhibited osteoclastogenesis by 
down regulating NFATc1 and inflammatory mediators such as TNF-α, they also upregulated OB 
transcription factors such as Runx2, Osterix and IGF-1 in MC3T3-E1 cells [16].  In another study 
involving dried plum in ovariectomized rats, trabecular micro-architectural parameters were 
improved as well as femoral and tibial BMD by the 5% dose while lumbar BMD was improved 
at a 25% dose [17].   
The pro-vitamin A compound, β-carotene, found in mango may also play a role in OB 
cell differentiation.  Research done by Park and colleagues on mouse osteoblastic cells 
demonstrated that vitamin A and carotenoids increased OB cell differentiation[204] while another 
cell culture study showed an inhibited OC like cell formation[205].  In a study involving 334 men 
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and 540 women over the age of 75,  a positive correlation between carotenoid consumption and 
BMD [18] and a negative correlation with carotenoid consumption and hip fracture rates was 
observed [206].  A study conducted by Yuyama and colleagues determined that the pro vitamin A 
carotenoids in mango was absorbed with 82% efficiency in rats[207].  Drammeh and colleagues 
used dried mango powder along with fat supplementation to successfully improve the vitamin A 
status in young Gambian children[208].  These findings suggest that pro vitamin A content of the 
mango in the present study may influence bone.  The present study, however, demonstrated that 
mango, despite being a rich source of antioxidants and β-carotene, was not able to reverse bone 
loss.   
As expected, the OVX mice experienced more bone resorption than the SHAM control 
mice.  Mango did not attenuate bone resorption as evidenced by serum PYD values that were 
similar between the mango groups and the OVX control mice.  Despite PINP being one of the 
most specific and sensitive indicators of bone formation[209], serum PINP levels were not 
significantly different between any of the groups.  The trend (P = 0.0510) was that SHAM mice 
had the highest PINP levels with 25% mango group exhibiting the lowest values.  Considering 
this trend along with the fact that the mango group mice exhibited a lower body fat body 
composition, one may want to consider the influence of the metabolically active adipose tissue 
on bone parameters. 
The higher body fat composition in the OVX mice may exhibit a greater hormonal effect 
contributing to increased rates of bone formation.  For example, earlier studies have 
demonstrated that leptin, secreted by the adipose tissue, stimulates cortical bone formation[74, 75] 
via its effects on the GH-IGF-1 axis of the central nervous system and by suppressing the release 
of neuropeptide Y, an inhibitor of cortical bone formation, from the hypothalamus.  Leptin’s 
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combined effects of neuropeptide Y suppression and the β1- adrenergic stimulation result in an 
increase in cortical bone mass  [74].  Adiponectin, also secreted by adipose tissue, is known to 
modulate glucose and fatty acid catabolism [210] with levels inversely associated with percent 
body fat [211].  In a study conducted on postmenopausal women, increasing adiponectin levels 
were associated with a decrease in BMD.  The percent change in BMD was associated with a 
doubling in serum adiponectin levels [212].  A study conducted by Richards and colleagues 
showed that serum adiponectin levels were associated with a 2.7% average decrease in BMD at 
the hip, femoral neck, forearm and spine[213, 214].  Post-menopausal status increased the 
magnitude of this inverse relationship.  The fact that the decrease in BMD was also evident at 
non-weight bearing sites indicates an important role of adipose hormones in regulating BMD.  
Future implications of this research may want to consider the effects of adipose hormones on 
BMD.   
Although mango fed for 8 weeks was not effective in reversing bone loss, mango 
modulated body weight and body composition.  Mango attenuated weight gain and percent body 
fat.  After four weeks of dietary treatment, both mango diet groups weighed less than the OVX 
control group.  Final body weight of the 25% mango diet group was similar to both the 5% 
mango group and that of the SHAM mice.  Similarly, fat mass and % body fat of both mango 
diet mice groups were less than that of the OVX control mice despite similar food intake patterns 
between all OVX groups.  Following suit, both mango containing diets had more fat free mass 
than the OVX control mice.  Although the fiber content of the mango and control groups were 
matched, mango may have exerted an effect on digestion or absorption of the diet either by 
inhibiting fat absorption to a degree or by increasing the metabolism.  Stool assessments or direct 
calorimetry may be ways to assess these possibilities in the future studies. Further investigation 
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on mango and bone biology and mechanisms in modulating body composition in 
postmenopausal women are warranted.   
The results of our study failed to reject our null hypotheses.  Freeze-dried mango powder 
in 5% and 25% of the daily diet was not effective in reversing ovariectomy induced bone loss in 
mice.  Mango did not improve whole body, tibial or lumbar vertebral BMD , nor did it improve 
micro-architectural parameters or bone strength in the vertebrae.  Plasma markers of bone 
formation (PINP) and bone resorption (PYD) also were not affected by mango supplementation.  
Freeze-dried mango powder supplementation in both doses did attenuate weight gain and 
modulate body composition.  Although mango was not able to reverse the bone lose associated 
with gonadal hormone difficiency, its role in preventing osteoporosis still needs to be explored.   
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